Philips Respironics Product Recall: Important Information for Careica Clients

Tuesday, June 28, 2022

Careica Health is in close contact with Philips Respironics to stay up-to-date on the issue. We will continue to update this blog post with new information as it becomes available.

UPDATE: June 28, 2022

Philips Respironics has issued an update regarding the recall. Please see below for a link to the full press release.

There is a video at the end of the release featuring Philips CEO Frans van Houten and Chief Business Leader Connected Care Roy Jakobs that may be of interest.


UPDATE: March 31, 2022

Philips Respironics has begun processing recalled CPAP devices. Careica Health will be assisting all clients who purchased a recalled device from us. If you have purchased a recalled device from Careica Health, no action is required by you—we will call you. We will be contacting our clients in a specific order to ensure the most vulnerable people receive assistance first.

Please note: If your medical condition has changed, it is important to call us at 1-888-297-7889 as it could affect the order in which you are assisted.


UPDATE: December 8, 2021

Careica Health recognizes the impact that the global CPAP shortage is having on our clients’ therapy. While we continue to wait for further information and replacement CPAP machines from Phillips Respironics, we remain committed to communicating directly with our clients and referring physicians and will do so as soon as information becomes available.

For an interesting perspective on how the Philips Respironics CPAP recall and global supply chain issues are affecting all of us, please click on this link for a message from ResMed’s CEO, Mick Farrell. ResMed is a major global manufacturer of CPAP equipment. 

We appreciate your patience and understanding as we continue to work through these on behalf of our clients.

Original notice:
 June 16, 2021

Philips Respironics is voluntarily recalling a number of medical devices including Dreamstation and System One CPAPs. For your immediate reference Philips Respironics makes the following statement regarding foam degradation exposure:

Potential Hazard: Philips has determined from user reports and lab testing that under certain circumstances the foam may degrade into particles which may enter the device’s air pathway and be ingested or inhaled by the user of its Continuous Positive Airway Pressure (CPAP), BiLevel Positive Airway Pressure (BiLevel PAP) and Mechanical Ventilator devices. The foam degradation may be exacerbated by environmental conditions of higher temperatures and humidity in certain regions. Unauthorized cleaning methods such as ozone may accelerate potential degradation." 



More information regarding this recall

Communication from Philips Respironics, including a comprehensive list of recalled devices:


Philips Respironics portal to register your recalled device:



Medical guidance regarding this recall

For your immediate reference, the July 9, 2021 joint position statement by The Canadian Thoracic Society, Canadian Sleep Society and the Canadian Society of Respiratory Therapists states:

  • For patients using affected CPAP or Bi-Level devices at night for obstructive sleep apnea, we would advise contacting their physician in a timely fashion to decide on the best course of action and continuing using their device in the meantime.
  • For patients who develop symptoms compatible with irritation from foam degradation particles such as cough, headaches, sinus infections that started after starting on PAP treatment OR who notice particles in their humidifier chamber, tubing or mask; they should contact their physician as soon as possible to discuss options and they should be considered a priority for clinical decision-making.



Have a question regarding this recall? Give us a call.

If you need any further information or support concerning this recall, please contact Careica Health at 1-888-297-7889.